Cytokine News and Research

RSS

Could ultra-low dose radiotherapy treat COVID-19-related pneumonia?

Researchers at the Department of Radiation Oncology, La Milagrosa Hospital, GenesisCare, Madrid, Spain, showed the potential benefit of treating COVID-19 pneumonia with ultra-low doses of radiotherapy.

2 Feb 2021

SARS-CoV-2 triggers development of new-onset IgG autoantibodies in hospitalized COVID-19 patients

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent for coronavirus disease 2019 (COVID-19), is associated with several clinical features common in autoimmune diseases as myalgias, arthralgias, fatigue, and rashes. COVID-19 patients also exhibit less common autoimmunity manifestations such as myositis, thrombosis, myocarditis, encephalitis, vasculitis, and arthritis.

1 Feb 2021

Can metformin reduce mortality in diabetic individuals with severe COVID-19?

A new study by researchers in China and the U.S. describes a round-up of the effects of commonly used hypoglycemic drugs on the outcomes of COVID-19 in diabetic patients.

1 Feb 2021

Colchicine may have therapeutic potential against COVID-19

A new study describes the results of colchicine in mitigating the inflammatory storm associated with COVID-19, and thus preventing a percentage of severe and critical cases.

1 Feb 2021

Synergistic effect between NF-κB inhibitors and zinc in vitro reducing ACE2 expression

Researchers at National Taiwan University Hospital in Taipei have conducted a study demonstrating the potential effectiveness of a novel drug combination at reducing morbidity and mortality in coronavirus disease 2019 (COVID-19).

31 Jan 2021

Anakinra shows therapeutic potential in critically ill COVID-19 patients

A team of international scientists recently conducted an open-level clinical trial to investigate the effects of personalized immunotherapy on critically ill COVID-19 patients.

27 Jan 2021

Could spironolactone treat COVID-19-related pneumonia and pulmonary fibrosis?

Researchers have described the potential of the drug spironolactone, a potassium-sparing diuretic, and anti-androgen, in preventing or alleviating the severity of COVID-19 pneumonia, and in preventing pulmonary fibrosis.

27 Jan 2021

What do we know about the SARS-CoV-2 vaccines so far?

A new study surveys what we know so far about SARS-CoV-2 vaccine candidates from advanced clinical trials.

27 Jan 2021

Antibodies and inflammatory markers may help identify COVID-19 cases and predict severity

A new preprint appearing on the medRxiv server describes the changes that occur in numerous antibodies and inflammatory molecules with age and at varying stages, or severity, of the infection and resulting illness. The results may help to predict the risk in individual cases.

26 Jan 2021

Researchers develop method for presymptomatic COVID-19 detection

An encouraging new study by researchers at University College London, UK, reports the potential of a form of COVID-19 testing which can detect presymptomatic cases.

26 Jan 2021

Hyperinflammatory conditions drive gender differences in COVID-19 severity and mortality

Recently researchers from India analyzed gender differences in COVID-19-related hyperinflammatory conditions resulting in mortality in Indian patients. The study is published on the preprint server, medRxiv*.

25 Jan 2021

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

With the emergence of COVID-19 (coronavirus disease 2019), researchers have been closely investigating the complex interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the human immune system, and COVID-19 disease severity.

25 Jan 2021

Experts advise disaggregating data on COVID-19 patients by sex

Researchers at Yale University School of Medicine have highlighted the importance of ensuring studies of patients with coronavirus disease 2019 (COVID-19) report data in a sex-disaggregated manner.

24 Jan 2021

Study examines risk factors for developing ME/CFS in college students after infectious mononucleosis

Many college students fully recover from infectious mononucleosis (which is almost always caused by Epstein-Barr virus) within 1-6 weeks, but some go on to develop chronic fatigue syndrome, also called myalgic encephalomyelitis (ME/CFS).

22 Jan 2021

NSAIDs dampen antibody and inflammatory responses to SARS-CoV-2 infection in mice

New research shows that non-steroidal anti-inflammatory drugs (NSAIDs) reduced both antibody and inflammatory responses to SARS-CoV-2 infection in mice. The study appears this week in the Journal of Virology, a publication of the American Society for Microbiology.

22 Jan 2021

Novel neutralizing antibodies targeting SARS-CoV-2 N-terminal domain discovered

A new study by US-based researchers shows the presence of protective antibodies that target the N-terminal domain (NTD) of the spike instead of the spike receptor-binding domain (RBD).

22 Jan 2021

SARS-CoV-2’s nonstructural proteins dysregulate immune responses, study finds

Researchers provide an overview of SARS-CoV-2 and its life cycle pathways, addressing the functional changes in the viral proteins, providing important strategic clues to help that may help in the ongoing development of therapies against COVID-19.

22 Jan 2021

SARS-CoV-2 suppresses host innate immunity

SARS-CoV-2, the virus that causes COVID-19, blocks the processes of innate immune activation that normally direct the production and/or signaling of type I interferon (IFN-I) by the infected cell and tissues.

21 Jan 2021

Kruppel-like factor 2 may be a major determinant of acute respiratory distress syndrome in COVID-19 patients

A study conducted at the University of Chicago, USA, has recently revealed that downregulation of an endothelial transcription factor, Kruppel-like factor 2, by SARS-CoV-2 is responsible for ARDS frequently observed in critically ill COVID-19 patients.

19 Jan 2021

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

A new study suggests that modified natural killer cells, which express a chimeric antigen receptor using S309 antibody, can bind to and inactivate SARS-CoV-2 spike protein in vitro.

18 Jan 2021

Cytokine News and Research

Could ultra-low dose radiotherapy treat COVID-19-related pneumonia?

SARS-CoV-2 triggers development of new-onset IgG autoantibodies in hospitalized COVID-19 patients

Can metformin reduce mortality in diabetic individuals with severe COVID-19?

Colchicine may have therapeutic potential against COVID-19

Synergistic effect between NF-κB inhibitors and zinc in vitro reducing ACE2 expression

Anakinra shows therapeutic potential in critically ill COVID-19 patients

Could spironolactone treat COVID-19-related pneumonia and pulmonary fibrosis?

What do we know about the SARS-CoV-2 vaccines so far?

Antibodies and inflammatory markers may help identify COVID-19 cases and predict severity

Researchers develop method for presymptomatic COVID-19 detection

Hyperinflammatory conditions drive gender differences in COVID-19 severity and mortality

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

Experts advise disaggregating data on COVID-19 patients by sex

Study examines risk factors for developing ME/CFS in college students after infectious mononucleosis

NSAIDs dampen antibody and inflammatory responses to SARS-CoV-2 infection in mice

Novel neutralizing antibodies targeting SARS-CoV-2 N-terminal domain discovered

SARS-CoV-2’s nonstructural proteins dysregulate immune responses, study finds

SARS-CoV-2 suppresses host innate immunity

Kruppel-like factor 2 may be a major determinant of acute respiratory distress syndrome in COVID-19 patients

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News